Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps are being taken to make Kaftrio available for the treatment of cystic fibrosis in the UK.

Kaftrio is available to National Health Service patients in England in line with its licence through a four year interim access deal negotiated between NHS England and NHS Improvement and Vertex, the drug manufacturer. NHS England and NHS Improvement are committed to expanding patient access to Kaftrio to cover any future licence extensions. The availability of medicines elsewhere in the United Kingdom is a devolved matter.